ArticleJournal of hepatocellular carcinoma2026
Efficacy of Lenvatinib versus Bevacizumab in Triple Therapy with Immune Checkpoint Inhibitors and Interventional Therapy for Hepatocellular Carcinoma with Macrovascular Invasion: A Multi-Center Real-World Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) patients with macrovascular invasion (MaVI) continue to experience a dismal prognosis and the optimal drug combination choices remain undefined. The aim of this study was to compare the clinical efficacy and safety of lenvatinib-based triple therapy versus bevacizumab-based triple therapy, as first-line treatment for patients with MaVI. Patients and Methods: This retrospective multicenter study enrolled 184 consecutive patients from three centers in China, all of whom received first-line lenvatinib (n=126) or bevacizumab (n=58) combined with immune checkpoint inhibitors (ICIs) and interventional therapy (TACE and/or HAIC). The primary endpoints were progression-free survival (PFS) and overall survival (OS). Propensity score matching (PSM) was applied to balance baseline clinical characteristics, and inverse probability of treatment weighting (IPTW) was subsequently applied to assess the robustness of the findings. Results: In the overall cohort, median PFS did not differ significantly between the lenvatinib group and the bevacizumab group (hazard ratio [HR]: 0.694; 95% confidence interval [CI]: 0.477-1.008; P = 0.053). However, the PFS difference reached statistical significance after PSM (8.40 months in the lenvatinib group vs 13.00 months in the bevacizumab group; HR: 0.601; 95% CI: 0.389-0.928; P = 0.02) and after IPTW (HR: 0.609; 95% CI: 0.415-0.894; P = 0.011). No significant difference in OS was observed between the two groups in the unadjusted cohort (HR: 0.809; 95% CI: 0.512-1.279; P = 0.362), after PSM (20.23 vs 35.20 months; HR: 0.634; 95% CI: 0.376-1.069; P = 0.085), or after IPTW (HR: 0.686; 95% CI: 0.432-1.089; P = 0.11). Multivariate analysis in the matched cohort showed that bevacizumab-based triple therapy was associated with prolonged PFS compared with lenvatinib-based triple therapy. There was no significant difference between the two groups in the incidence of grade 3-4 adverse events (58.57% vs 66.00%, P = 0.409) and grade 3-4 gastrointestinal hemorrhage (12.86% vs 8.00%, P = 0.399). Conclusion: In HCC patients with MaVI, bevacizumab-based triple therapy was associated with prolonged PFS compared to lenvatinib-based triple therapy, with no significant difference in OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.